PubLications (confERENCE abstracts)

1

S. Sundar, L Furber, D Cameron, P Leonard, C Humber, A Thomas, WP Steward, KJ O’Byrne. Phase I/II Study of Docetaxel in combination with the P-Glycoprotein-170 inhibitor Valspodar in Solid tumours. Proc Am Soc Clin Oncol 2002; 21(2): 92b. 2182.

2

S. Santhanam, M Decatris, F J Madden. Trends in survival of patients diagnosed with primary Testicular tumours in Leicestershire: a 15-year experience (1983 – 1997). British Journal of Cancer. 2002. Vol 86 (suppl 1): S57. P76.  

3

S. Santhanam, S Bolton, S Vasanthan, G Thomas. Safe delivery of Radiotherapy to patients with Implanted Cardiac Pacemakers. British Journal of Cancer. 2002.Vol 86 (suppl 1): S65. P103. 

4

M P Decatris, K Jeffries, S. Santhanam, A Thomas, S Khanna, S Vasanthan, A Benghiat, R P Symonds, K O’Byrne, W P Steward. A Prospective Audit of Peripherally Inserted Central venous Catheters (PICCs). British Journal of Cancer. 2002.Vol 86 (suppl 1): S69. P117.

5

S. Sundar, A. Basu, M. Liddicoat, S.Vasanthan. Assessment of local spread and nodal metastatic disease in Prostate cancer: Correlation between Partin Tables (a staging nomogram) and MR Imaging features. European Radiology. 2002. Vol 12(6):D6-D7. 

6

S. Santhanam, F J Madden. Patterns of Radiotherapy usage in 328 consecutive primary Testicular tumour patients: a 15-year experience (1983 to 1997). Radiotherapy and Oncology. 2002. Vol 64 (suppl 1): S304. P1041.  

7

S. Sundar, A Mitchell, M Decatris, M Kumar, A Osman, S Khanna, S Vasanthan, P Symonds, K O'Byrne. Phase II study of Oxaliplatin  and 5-Fluorouracil/Leucovorin combination in patients with Epithelial Ovarian Cancer relapsing within 2 years of platinum based therapy. Annals of Oncology.2002.Vol 13 (Suppl 5):112. 410P.  

8

S Mon, C Murray, S Sundar, T McCulloch, SY Chan. Analysis of DNA ploidy in borderline ovarian tumours. Proc Am Soc Clin Oncol 2003. A1968

9

AJ.Colquhoun, S. Santhanam, PH.Rajjayabun, RP. Symonds, JK. Mellon.  Can inhibition of epidermal growth factor receptor (EGFR) with gefitinib (ZD1839) improve the response to radiation therapy in bladder cancer?. Proc Am Soc Clin Oncol 2003. A919

10

M Decatris, S. Sundar, K O'Byrne.  Platinum-based chemotherapy in metastatic breast cancer (MBC): The Leicester (UK) experience. Annals of Oncology.2003; 14: (iii) 56.  

11

A.Colquhoun, S.Sundar, P.Rajjayabun, L.Griffiths, P.Symonds, K.Mellon. Epidermal growth factor receptor (EGFR) status predicts outcome following external beam radiation therapy for muscle-invasive bladder cancer. EAU Annual Congress.Vienna, 2004.

12

S Sundar, M Sokal, K Lees, L Osborne, J Carmichael. Phase II trial of Gemcitabine Carboplatin Combination in advanced transitional cell cancer (TCC) of bladder and urinary tract. Annals of Oncology. 2004; 15 Suppl 3;iii.118. 441P

13

RP. Symonds, DM.Kumar, S.Sundar, K.Ibrahim, B Savelyich, E.Miller. Information needs of Asian and White English cancer patients and their families in Leicestershire: a cross-sectional survey. British Journal of Cancer.2003: 88 (Suppl 1): S24: 7.8

14

S. Sundar, D.Fyfe, A.Dhadda, S.Khan,A.Conn. Impact of Neutropenia on delivering planned Chemotherapy for Solid tumors. Ann Oncol 2005. Vol 16,Suppl 2: ii320. 185P

15

A Dhadda, D Lakshmanan, M Sokal, S Sundar . Age does not influence acute toxicity during radiotherapy dose escalation for prostate cancer. European Journal of Cancer Supplements. ECCO 13 Abstract Book. October 2005. Volume 3, Issue 2, Pages 3-542. Abstract no: 1.279..

16

S.Sundar, A Wade, D Lakshmanan, A Dhadda, M Sokal. Male Cancer Patients' attitudes towards female physicians, female nurses and chaperones during Urological consultations. European Journal of Cancer Supplements. ECCO 13 Abstract Book. October 2005. Volume 3, Issue 2, Pages 3-542. Abstract no: 1.327

17

Helal AM, Sundar S, Przeslak AJ, Perkins AC. A comparison of 3D conformal radiotherapy and IMRT treatment plans in prostate cancer. European Journal of Cancer Supplements. ECCO 13 Abstract Book. October 2005. Volume 3, Issue 2, Pages 3-542. Abstract no: 849.

18

C Joynson, P Symonds, S Sundar. Anaemia in patients with transitional cell carcinoma (TCC) of the bladder treated with radiotherapy. Journal of Clinical Oncology. 2006. Volume 24 (18S). 642: A14569.

19

A Helal S Sundar et al. The effect of target volume / OAR geometry on the dose distribution within rectum and bladder for IMRT treatment of prostate cancer. NCRI 2006 Cancer Conference. Birmingham B54: P101

20

A Chaudhuri, S S undar. et al.  The utility of routine urine cultures and serum biochemistry in prostate cancer patients undergoing radical 3D-conformal external beam radiotherapy. NCRI 2006 Cancer Conference. Birmingham. B53: P100

21

C Joynson, P Symonds, S Sundar. Anaemia in patients with transitional cell carcinoma (TCC) of the bladder treated with radiotherapy. NCRI 2006 Cancer Conference. Birmingham. B150: P132

22

A. M. Helal, A. Przeslak, S. Sundar, A. Perkins. Patient geometry and applicability of class solution for optimised intensity modulated radiotherapy dose distributions for prostate cancer. ASCO 2007 Prostate Cancer Symposium. Abstract no: 372. 

23

Song, X., Petrovic, S., Sundar, S. “A Case-Based Reasoning Approach to Dose Planning in Radiotherapy”, in D.Wilson, D.Khemani (Eds.) Workshop Proceedings, The Seventh International Conference on Case-Based Reasoning ICCBR'07, Belfast, Northern Ireland, August 13-16, 2007, pp. 348-357.

24

Petrovic,S., Leung,W., Song,X., and Sundar,S., "Algorithms for radiotherapy treatment booking", in R.Qu (Ed) Proceedings of the 25th Workshop of the UK Planning and Scheduling Special Interest Group (PlanSIG'2006) , Nottingham, UK, 14-15th December 2006, pp. 105-112.

25

S. Sundar, R. Cox. Re-induction of sensitivity to diethylstilbestrol in docetaxel-treated androgen refractory prostate cancer. ASCO 2008 Prostate Cancer Symposium. Abstract No: 172

26

Mishra N, Petrovic S, Sundar S, A Knowledge-light Nonlinear Case-based Reasoning Approach to Radiotherapy Planning, Proceedings of the 21st International Conference on Tools with Artificial Intelligence, ICTAI 2009, November 2-5, 2009, Newark USA, 776-783.

27

N. Mishra, S. Petrovic and S. Sundar, A Novel Case Based Reasoning Approach to Radiotherapy Planning, in Proceedings of the 18th Triennial Conference of the International Federation of Operational Research Societies (IFORS'08), Sandton, South Africa, 13-18 July, 2008, pp. 66.

28

N. Mishra, S. Petrovic, S. Sundar, A non-linear case based reasoning approach to radiotherapy dose planning, in Proceedings of the 35th annual Operational Research Applied to Health Services (ORAHS) Leuven, Belgium, 12-17 July, 2009, pp. 24. .pdf

29

N. Mishra, S. Petrovic, S. Sundar, Self-adaptive case based reasoning for dose planning in radiotherapy, in book of the 36th annual Operational Research Applied to Health Services (ORAHS), 18-23 July, 2010, pp. 28-46. .pdf

30

N. Mishra, S. Petrovic, S. Sundar, A novel case based reasoning approach to radiotherapy planning, Expert Systems with Applications, accepted for publication. .pdf   Expert Systems with Applications: Volume 38 Issue 9, September, 2011.http://dl.acm.org/citation.cfm?id=1975071

31

Richard Cox, Santhanam Sundar. Diethylstilboestrol is active in docetaxel treated androgen independent prostate cancer. NCRI Conference Abstracts. 2008. C115

32

D. Peel, S. Sundar. Metronomic Cyclophosphamide and Dexamethasone is Active in Docetaxel, Castration Refractory, Prostate Cancer. Clinical Oncology. Volume 21, Issue 10, December 2009, Page 801.

33

O. Matzinger; F. Duclos; A. Van den Bergh; C. Carrie; P. Kitsios; S. Villa; P. Poortmans; S. Sundar; L. Collette; M. Bolla. Acute toxicity of curative radiotherapy for intermediate risk localized prostate cancer in the EORTC trial 22991. European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 151. Abstract O-2001. 

34

Abi Pascoe, S Sundar. Prostate Radiation for Castration Refractory Prostate cancer.  The 8th BUG Annual Meeting. September 2011. York. Clinical Oncology. Volume 24, Issue 2, March 2012, Pages 156.

35

R.A. Cox, E. Ferguson, S. Sundar . Validation of a Rating Scale to Assess the Effects of Testosterone Deficiency in Prostate Cancer Patients Taking Androgen Deprivation Therapy as an Adjunct to Radical Radiotherapy. EMCC. September 2011  European Journal of Cancer Vol. 47 Supplement 1, Page S497

36

A. Cox, N. Mishra, I. Sayers, S. Petrovic, S. Sundar. A Decision Aid for Radiotherapy Dose Selection in Prostate Cancer Based on Non-linear Case Based Reasoning . Clinical Oncology, Volume 23, Issue 3, April 2011, Pages S19-S20

37

P. Hoskin, S. Sundar, K. Reczko, S. Forsyth, N. Mithal, B. Sizer, L. Toy, M. Stratford, M. Jitlal et al.  A Multicentre Randomised Trial of Ibandronate Compared to Single Dose Radiotherapy for Localised Metastatic Bone Pain in Prostate Cancer (RIB). EMCC.  September 2011  European Journal of Cancer Vol. 47 Supplement 2, Page 6

38

Amit Bahl, Susan Masson, Zafar Malik, Alison J Birtle, Santhanam Sundar, Robert J Jones, Nicholas David James, Malcolm David Mason, Satish Kumar, David Bottomley, Anna Lydon, Simon Chowdhury, James Wylie, Johann Sebastian De Bono. Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279). 2012 Genitourinary Cancers Symposium . Abstract No: 44. J Clin Oncol 30, 2012 (suppl 5; abstr 44).

39

Bahl, A.K., Masson, S., Malik, Z., Birtle, A., Sundar, S., Jones, R., James, N., Mason, M., Kumar, S., Bottomley, D., Lydon, A., Chowdhury, S., Wylie, J., De Bono, J.. Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Interim Safety and Quality of Life (QOL) Data From the UK Early Access Programme. 27th Annual EAU Congress in Paris on 24-28 February 2012. Abstract no 129

40

G.A. Walker, C.J. Perry, S.Sundar. Radical prostate radiotherapy to M0 patients with a presenting PSA of more than 100. (ESTRO 31. Barcelona)  Radiotherapy and Oncology 2012. Vol. 103: Supplement 1, Page S431

41 C.J. Perry, G.A. Walker, S. Sundar . Does rectal diameter affect acute toxicity of radical radiotherapy for prostate cancer? (ESTRO 31. Barcelona) Radiotherapy and Oncology 2012: Vol. 103: Supplement 1, Page S430